Prelude Capital Management’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Prelude Capital Management’s Portfolio BIS Stock Details BIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,250	Closed	-$287K	–	1269
2015 Q4	$287K	Hold	1,250	–	–	0.04%	426
2015 Q3	$386K	Sell	1,250 -188	-13%	-$44.4K	0.06%	341
2015 Q2	$330K	Buy	1,438 +1,300	+942%	+$323K	0.05%	425
2015 Q1	$38K	Buy	+138	New	+$42.2K	0.01%	1476

Other funds holding BIS

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Prelude Capital Management's BIS Position: Q1 2016 in Review

Prelude Capital Management sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q1 2016, closing a stake of 1,250 shares — an estimated $287K sold.

Prelude Capital Management first reported a position in BIS in Q1 2015 and held it in 4 quarters. The position peaked at $386K in Q3 2015. 14 funds tracked by Wall St. Rank hold BIS as of Q1 2016.

Prelude Capital Management reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q1 2016 after selling out during the quarter.
Prelude Capital Management sold 1,250 ProShares UltraShort NASDAQ Biotechnology shares in Q1 2016, an estimated $287K.
Prelude Capital Management first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q1 2015 and held it in 4 quarters.
Prelude Capital Management's ProShares UltraShort NASDAQ Biotechnology position peaked at $386K in Q3 2015.
14 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q1 2016.

Based on Prelude Capital Management's 13F filing for Q1 2016, filed 16 May 2016.